銀杏 Ginkgo Biloba

INT-ginkgo-biloba-001 4 個適應症被研究
D 3 U 1

適應症與證據等級

法規與權威立場 (L4)

L4a · US FDA
立場:cautious
Most consider the main benefit of Ginkgo biloba to be its ability to prevent the worsening of memory problems due to … neurodegenerative disease.
來源 ↗
L4b · EU EFSA
立場:not_addressed
Some 'general function' claims (1548 botanical-related claims) have been put on hold pending for the Commission and Member States final consideration.
來源 ↗
L4c · UK NHS
立場:cautious
Some people with dementia and their carers use complementary remedies, such as gingko biloba, curcumin or coconut oil. However, there's not enough evidence to say whether such remedies are effective. ... It's best to be wary of any products that claim to benefit people with dementia. If you're thinking of taking such a product or supplement, it's important to consult a doctor first. Some remedi…
來源 ↗
L4d · TW TFDA / 衛福部
立場:cautious
銀杏果(俗稱白果)屬於一般食品,並無療效。而銀杏葉萃取物,在我國是以藥品管理。其效果僅限於改善末梢血液循環,對於老年失智、中風及動脈血管疾病,並未證實有治療效果。
來源 ↗
L4e · WHO
立場:neutral
WHO monographs on selected medicinal plants - Volume 1
來源 ↗

市場與行銷 (L10)

L10a · TW Market Channels
永信HAC 銀杏果錠 180錠 $1,300
L10b · TW Legal Identity (TFDA)
銀杏葉萃取物,在我國是以藥品管理
L10c · TW Community (PTT/Dcard/Mobile01)
銀杏早證實無效了